{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T09:55:30Z","timestamp":1770890130856,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T00:00:00Z","timestamp":1595289600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T00:00:00Z","timestamp":1595289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologe"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s00347-020-01170-x","type":"journal-article","created":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T12:03:41Z","timestamp":1595333021000},"page":"873-885","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbands der Augen\u00e4rzte Deutschlands zur Anti-VEGF-Therapie der Fr\u00fchgeborenenretinopathie","Statement of the German Ophthalmological Society, the German Retina Society and the Professional Association of German Ophthalmologists on anti-VEGF therapy of retinopathy of prematurity"],"prefix":"10.1007","volume":"117","author":[{"name":"Deutsche Ophthalmologische Gesellschaft e.\u202fV. (DOG)","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Retinologische Gesellschaft e.\u202fV. (RG)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Berufsverband der Augen\u00e4rzte Deutschlands e.\u202fV. (BVA)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,21]]},"reference":[{"key":"1170_CR1","doi-asserted-by":"publisher","first-page":"F21","DOI":"10.1136\/archdischild-2013-303799","volume":"99","author":"J Aitken","year":"2014","unstructured":"Aitken J, Williams FLR (2014) A systematic review of thyroid dysfunction in preterm neonates exposed to topical iodine. Arch Dis Child Fetal Neonatal Ed 99:F21\u2013F28. https:\/\/doi.org\/10.1136\/archdischild-2013-303799","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"1170_CR2","doi-asserted-by":"publisher","DOI":"10.1055\/a-1012-1999","author":"M Andrassi-Darida","year":"2019","unstructured":"Andrassi-Darida M, Mais C, Stieger K, Lorenz B (2019) Fluorescence angiography-assisted management of recurrences in aggressive posterior retinopathy of prematurity (APROP) after Intravitreal monotherapy with 0.312\u202fmg Bevacizumab. Klin Monbl Augenheilkd. https:\/\/doi.org\/10.1055\/a-1012-1999 (online im Druck)","journal-title":"Klin Monbl Augenheilkd"},{"key":"1170_CR3","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1136\/bjophthalmol-2014-305252","volume":"98","author":"RL Avery","year":"2014","unstructured":"Avery RL, Castellarin AA, Steinle NC et al (2014) Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol 98:1636\u20131641. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305252","journal-title":"Br J Ophthalmol"},{"key":"1170_CR4","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","volume":"121","author":"Early Treatment For Retinopathy Of Prematurity Cooperative G","year":"2003","unstructured":"Early Treatment For Retinopathy Of Prematurity Cooperative G (2003) Revised indications for the treatment of retinopathy of prematurity: results of the Early Treatment for Retinopathy of Prematurity Randomized Trial. Arch Ophthalmol 121:1684\u20131694","journal-title":"Arch Ophthalmol"},{"key":"1170_CR5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jaapos.2004.12.018","volume":"9","author":"E Garcia-Valenzuela","year":"2005","unstructured":"Garcia-Valenzuela E, Kaufman LM (2005) High myopia associated with retinopathy of prematurity is primarily lenticular. J\u00a0AAPOS 9:121\u2013128. https:\/\/doi.org\/10.1016\/j.jaapos.2004.12.018","journal-title":"J AAPOS"},{"key":"1170_CR6","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","volume":"132","author":"MM Geloneck","year":"2014","unstructured":"Geloneck MM, Chuang AZ, Clark WL et al (2014) Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a\u00a0randomized clinical trial. JAMA Ophthalmol 132:1327\u20131333. https:\/\/doi.org\/10.1001\/jamaophthalmol.2014.2772","journal-title":"JAMA Ophthalmol"},{"key":"1170_CR7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/00006982-199703000-00009","volume":"17","author":"RJ Hairston","year":"1997","unstructured":"Hairston RJ, Maguire AM, Vitale S, Green WR (1997) Morphometric analysis of pars plana development in humans. Retina 17:135\u2013138. https:\/\/doi.org\/10.1097\/00006982-199703000-00009","journal-title":"Retina"},{"key":"1170_CR8","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","volume":"130","author":"J Hu","year":"2012","unstructured":"Hu J, Blair MP, Shapiro MJ et al (2012) Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol 130:1000\u20131006. https:\/\/doi.org\/10.1001\/archophthalmol.2012.592","journal-title":"Arch Ophthalmol"},{"key":"1170_CR9","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00417-017-3878-4","volume":"256","author":"C-Y Huang","year":"2018","unstructured":"Huang C-Y, Lien R, Wang N-K et al (2018) Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 256:479\u2013487. https:\/\/doi.org\/10.1007\/s00417-017-3878-4","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1170_CR10","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1055\/s-2005-858231","volume":"222","author":"GB Jaissle","year":"2005","unstructured":"Jaissle GB, Szurman P, Bartz-Schmidt KU et al (2005) Recommendation for the implementation of intravitreal injections\u2014statement of the German Retina Society, the German Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmologists (BVA). Klin Monbl Augenheilkd 222:390\u2013395. https:\/\/doi.org\/10.1055\/s-2005-858231","journal-title":"Klin Monbl Augenheilkd"},{"key":"1170_CR11","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1167\/iovs.14-15842","volume":"56","author":"L Kong","year":"2015","unstructured":"Kong L, Bhatt AR, Demny AB et al (2015) Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity. Invest Ophthalmol Vis Sci 56:956\u2013961. https:\/\/doi.org\/10.1167\/iovs.14-15842","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1170_CR12","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s00347-012-2618-8","volume":"109","author":"TU Krohne","year":"2012","unstructured":"Krohne TU, Aisenbrey S, Holz FG (2012) Current therapeutic options in retinopathy of prematurity. Ophthalmologe 109:1189\u20131197. https:\/\/doi.org\/10.1007\/s00347-012-2618-8","journal-title":"Ophthalmologe"},{"key":"1170_CR13","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00347-018-0675-3","volume":"115","author":"PP Larsen","year":"2018","unstructured":"Larsen PP, Br\u00fcnder M-C, Petrak M et al (2018) Screening for retinopathy of prematurity: Trends over the past 5 years in two German university hospitals. Ophthalmologe 115:469\u2013475. https:\/\/doi.org\/10.1007\/s00347-018-0675-3","journal-title":"Ophthalmologe"},{"key":"1170_CR14","doi-asserted-by":"publisher","first-page":"e0148019","DOI":"10.1371\/journal.pone.0148019","volume":"11","author":"R Lien","year":"2016","unstructured":"Lien R, Yu M-H, Hsu K-H et al (2016) Neurodevelopmental outcomes in infants with retinopathy of prematurity and Bevacizumab treatment. PLoS ONE 11:e148019. https:\/\/doi.org\/10.1371\/journal.pone.0148019","journal-title":"PLoS ONE"},{"key":"1170_CR15","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.ophtha.2016.04.028","volume":"123","author":"HA Mintz-Hittner","year":"2016","unstructured":"Mintz-Hittner HA, Geloneck MM, Chuang AZ (2016) Clinical management of recurrent retinopathy of prematurity after intravitreal Bevacizumab monotherapy. Ophthalmology 123:1845\u20131855. https:\/\/doi.org\/10.1016\/j.ophtha.2016.04.028","journal-title":"Ophthalmology"},{"key":"1170_CR16","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ (2011) Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N\u00a0Engl J Med 364:603\u2013615. https:\/\/doi.org\/10.1056\/NEJMoa1007374","journal-title":"N Engl J Med"},{"key":"1170_CR17","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-3218","author":"J Morin","year":"2016","unstructured":"Morin J, Luu TM, Superstein R et al (2016) Neurodevelopmental outcomes following Bevacizumab injections for retinopathy of prematurity. Pediatrics. https:\/\/doi.org\/10.1542\/peds.2015-3218","journal-title":"Pediatrics"},{"key":"1170_CR18","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1136\/bjo.2009.162156","volume":"94","author":"CK Patel","year":"2010","unstructured":"Patel CK, Walker NJ, Kam JK (2010) A new, theoretically safer method of intravitreal injection of bevacizumab in progressive retinopathy of prematurity using scleral trans-illumination. Br J Ophthalmol 94:1107\u20131109. https:\/\/doi.org\/10.1136\/bjo.2009.162156","journal-title":"Br J Ophthalmol"},{"key":"1170_CR19","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1001\/archopht.123.7.991","volume":"123","author":"International Committee for the Classification of Retinopathy of Prematurity","year":"2005","unstructured":"International Committee for the Classification of Retinopathy of Prematurity (2005) The international classification of retinopathy of prematurity revisited. Arch Ophthalmol 123:991\u2013999. https:\/\/doi.org\/10.1001\/archopht.123.7.991","journal-title":"Arch Ophthalmol"},{"key":"1170_CR20","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/s0161-6420(92)31968-2","volume":"99","author":"GE Quinn","year":"1992","unstructured":"Quinn GE, Dobson V, Repka MX et al (1992) Development of myopia in infants with birth weights less than 1251 grams. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology 99:329\u2013340. https:\/\/doi.org\/10.1016\/s0161-6420(92)31968-2","journal-title":"Ophthalmology"},{"key":"1170_CR21","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/s0161-6420(00)00527-3","volume":"108","author":"GE Quinn","year":"2001","unstructured":"Quinn GE, Dobson V, Siatkowski R et al (2001) Does cryotherapy affect refractive error? Results from treated versus control eyes in the cryotherapy for retinopathy of prematurity trial. Ophthalmology 108:343\u2013347. https:\/\/doi.org\/10.1016\/s0161-6420(00)00527-3","journal-title":"Ophthalmology"},{"key":"1170_CR22","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1001\/jamapediatrics.2017.4838","volume":"172","author":"A Stahl","year":"2018","unstructured":"Stahl A, Krohne TU, Eter N et al (2018) Comparing alternative Ranibizumab dosages for safety and efficacy in retinopathy of prematurity: a randomized clinical trial. JAMA Pediatr 172:278\u2013286. https:\/\/doi.org\/10.1001\/jamapediatrics.2017.4838","journal-title":"JAMA Pediatr"},{"key":"1170_CR23","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","volume":"394","author":"A Stahl","year":"2019","unstructured":"Stahl A, Lepore D, Fielder A et al (2019) Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. Lancet 394:1551\u20131559. https:\/\/doi.org\/10.1016\/S0140-6736(19)31344-3","journal-title":"Lancet"},{"key":"1170_CR24","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2020.0334","author":"DK Wallace","year":"2020","unstructured":"Wallace DK, Kraker RT, Freedman SF et al (2020) Short-term outcomes after very low-dose intravitreous Bevacizumab for retinopathy of prematurity. JAMA Ophthalmol. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.0334","journal-title":"JAMA Ophthalmol"},{"key":"1170_CR25","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s00347-018-0701-5","volume":"115","author":"JM Walz","year":"2018","unstructured":"Walz JM, Bemme S, Reichl S et al (2018) Treated cases of retinopathy of prematurity in Germany: 5-year data from the Retina.net ROP Registry. Ophthalmologe 115:476\u2013488. https:\/\/doi.org\/10.1007\/s00347-018-0701-5","journal-title":"Ophthalmologe"},{"key":"1170_CR26","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s00103-007-0337-0","volume":"50","author":"Kommission f\u00fcr Krankenhaushygiene und Infektionspr\u00e4vention beim Robert Koch-Institut","year":"2007","unstructured":"Kommission f\u00fcr Krankenhaushygiene und Infektionspr\u00e4vention beim Robert Koch-Institut (2007) Empfehlung zur Pr\u00e4vention nosokomialer Infektionen bei neonatologischen Intensivpflegepatienten mit einem Geburtsgewicht unter 1500\u202fg: Mitteilung der Kommission f\u00fcr Krankenhaushygiene und Infektionspr\u00e4vention beim Robert Koch-Institut. Bundesgesundheitsbl 50:1265\u20131303. https:\/\/doi.org\/10.1007\/s00103-007-0337-0","journal-title":"Bundesgesundheitsbl"},{"key":"1170_CR27","unstructured":"Deutsche Ophthalmologische Gesellschaft (DOG), Retinologische Gesellschaft (RG), Berufsverband der Augen\u00e4rzte Deutschlands (BVA), Deutsche Gesellschaft f\u00fcr Kinder- und Jugendmedizin (DGKJ), Berufsverband der Kinder- und Jugend\u00e4rzte e.\u202fV. (BVKJ), Bundesverband \u201eDas fr\u00fchgeborene Kind\u201c e.\u202fV. und Gesellschaft f\u00fcr Neonatologie und P\u00e4diatrische Intensivmedizin (GNPI) (2020) Augen\u00e4rztliche Screening-Untersuchung bei Fr\u00fchgeborenen: Gemeinsame Empfehlung von Deutsche Ophthalmologische Gesellschaft (DOG), Retinologische Gesellschaft (RG), Berufsverband der Augen\u00e4rzte Deutschlands (BVA), Deutsche Gesellschaft f\u00fcr Kinder- und Jugendmedizin (DGKJ), Berufsverband der Kinder- und Jugend\u00e4rzte e.\u202fV. (BVKJ), Bundesverband \u201eDas fr\u00fchgeborene Kind\u201c e.\u202fV. und Gesellschaft f\u00fcr Neonatologie und P\u00e4diatrische Intensivmedizin (GNPI). https:\/\/www.awmf.org\/leitlinien\/detail\/ll\/024-010.html. Zugegriffen: 17.07.2020"},{"key":"1170_CR28","unstructured":"Grundel\u00a0M, Br\u00fcnder\u00a0MC, Stahl\u00a0A, Grundel\u00a0B. Therapie der Fr\u00fchgeborenenretinopathie. In Vorbereitung."}],"container-title":["Der Ophthalmologe"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-020-01170-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-020-01170-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-020-01170-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T23:33:11Z","timestamp":1626823991000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-020-01170-x"}},"subtitle":["Stand: 18.05.2020","Released: 18 May 2020"],"short-title":[],"issued":{"date-parts":[[2020,7,21]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["1170"],"URL":"https:\/\/doi.org\/10.1007\/s00347-020-01170-x","relation":{},"ISSN":["0941-293X","1433-0423"],"issn-type":[{"value":"0941-293X","type":"print"},{"value":"1433-0423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,21]]},"assertion":[{"value":"21 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Siehe Tab.\u00a0 im Anhang.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}